Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LPO | P22079 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27698626 | 0.98 | FDPS (0.40) | FDPSKMT2AMEN1LPOCNR2 | |
| SCHEMBL950351 | 0.89 | FDPS (0.39) | FDPSKMT2AMEN1LPOCNR2 | |
| SCHEMBL11445146 | 0.86 | FDPS (0.42) | FDPSKMT2AMEN1LPOCNR2 | |
| SCHEMBL7154948 | 0.83 | FDPS (0.48) | FDPSKMT2AMEN1LPOCNR2 | |
| Bromide SCHEMBL29657458 | 0.81 | FDPS (0.47) | FDPSKMT2AMEN1LPOCNR2 | |
| SCHEMBL952297 | 0.79 | — | — | |
| SCHEMBL2398203 | 0.79 | FDPS (0.46) | FDPSKMT2AMEN1LPOCNR2 | |
| SCHEMBL7166348 | 0.79 | FDPS (0.46) | FDPSKMT2AMEN1LPOCNR2 | |
| SCHEMBL12580120 | 0.78 | HSP90AA1 (0.32) | KMT2ATSHR | |
| SCHEMBL27679741 | 0.78 | FDPS (0.42) | FDPSKMT2AMEN1LPOTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888523-B2 | Preparation of platinum(II) complexes | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2011-02-15 | — | — | US | claimed |
| US-7589225-B2 | Preparation of platinum(II) complexes | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2009-09-15 | — | — | US | claimed |
| EP-1789427-B1 | PREPARATION OF PLATINUM(II) COMPLEXES | PLATCO TECHNOLOGIES PROPRIETAR (ZA) | 2009-05-20 | — | — | EP | claimed |
| US-20080064895-A1 | Preparation of Platinum(II) Complexes | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2008-03-13 | — | — | US | claimed |
| CN-101018797-A | Preparation of platinum (II) complexes | PLATCO TECHNOLOGIES PROPRIETAR (ZA) | 2007-08-15 | — | — | CN | claimed |
| EP-1789427-A1 | PREPARATION OF PLATINUM(II) COMPLEXES | Platco Technologies (Proprietary) Limited (ZA) | 2007-05-30 | — | — | EP | claimed |
| EP-1704156-A1 | PLATINUM(II) COMPLEXES, PREPARATION AND USE | Platco Technologies (Proprietary) Limited (ZA) | 2006-09-27 | — | — | EP | claimed |
| WO-2006024897-A1 | PREPARATION OF PLATINUM(II) COMPLEXES | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2006-03-09 | — | — | WO | claimed |
| WO-2005051966-A1 | PLATINUM(II) COMPLEXES, PREPARATION AND USE | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2005-06-09 | — | — | WO | claimed |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-02-23 | — | — | US | disclosed |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20130197210-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2011798-B1 | Preparation of platinum (II) complexes | PLATCO TECHNOLOGIES PROPRIETARY LTD (ZA) | 2011-06-29 | — | — | EP | disclosed |
| EP-2330110-A1 | Platinum(II) complexes, preparation and use | Platco Technologies (Proprietary) Limited (ZA) | 2011-06-08 | — | — | EP | disclosed |
| WO-2007085957-A1 | PREPARATION OF PLATINUM (LL) COMPLEXES | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2007-08-02 | — | — | WO | disclosed |
| US-20070167643-A1 | Platinum (II) complexes, preparation and use | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2007-07-19 | — | — | US | disclosed |
| EP-1789427-A1 | PREPARATION OF PLATINUM(II) COMPLEXES | Platco Technologies (Proprietary) Limited (ZA) | 2007-05-30 | — | — | EP | disclosed |
| EP-1704156-A1 | PLATINUM(II) COMPLEXES, PREPARATION AND USE | Platco Technologies (Proprietary) Limited (ZA) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006024897-A1 | PREPARATION OF PLATINUM(II) COMPLEXES | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005051966-A1 | PLATINUM(II) COMPLEXES, PREPARATION AND USE | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | FDPS 318/4885KMT2A 4801/4885MEN1 1142/4885 |
| US-20070167643-A1 | Platinum (II) complexes, preparation and use | PDCD5, ORC3, PDCD2L | FDPS 515/4885KMT2A 3504/4885MEN1 1530/4885 |
| US-20080064895-A1 | Preparation of Platinum(II) Complexes | SLCO4C1, SLC10A6, OTC | FDPS 933/4885KMT2A 2943/4885MEN1 1588/4885 |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | FDPS 318/4885KMT2A 4801/4885MEN1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.